Current filters:

Hisamitsu Pharma

Hisamitsu announces positive Phase II results for Parkinson’s disease drug


Japanese drugmaker Hisamitsu Pharmaceutical’s has announced the results of a Phase II clinical study…

Asia-PacificHisamitsu PharmaLevodopaNeurologicalPharmaceuticalResearch

Noven's Brisdelle is first non-hormonal treatment for menopausal hot flashes to be approved by FDA


The US Food and Drug Administration on Friday (June 28) approved Noven Pharmaceuticals' Brisdelle (paroxetine)…

BrisdelleHisamitsu PharmaNorth AmericaNoven PharmaceuticalsparoxetinePharmaceuticalRegulationWomen's Health

FDA should not approve paroxetine or gabapentin for hot flashes, says Public Citizen


A drug approved to treat depression and other mental health disorders and another designed to prevent…

DepomedgabapentinHisamitsu PharmaNorth AmericaparoxetinePharmaceuticalRegulationWomen's Health

Noven files NDA for non-hormonal therapy for menopausal vasomotor symptoms


USA-based Noven Pharmaceuticals, a wholly-owned subsidiary of Japanese drugmaker Hisamitsu Pharmaceuticals…

Hisamitsu PharmaNorth AmericaNoven PharmaceuticalsPharmaceuticalRegulationWomen's Health

Back to top